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In a retrospective analysis 139 patients with hypertrophic cardio-
myopathy were followed up for 8.9 years (range 1 to 28 years). 
Patients were divided into two groups: Group 1 consisted of 60 
patients with medical therapy and Group 2 of 79 patients with 
surgical therapy (septal myectomy). Groups 1 and 2 were 
subdivided according to the medical treatment. Group la re-
ceived propranolol, 160 mg/day (n = 20); Group Ib verapamil, 
360 mg/day (n = 18); and Group lc, no therapy (n = 22). Group 
2a received verapamil, 120 to 360 mg/day, after septal myectomy 
(n = 17) and Group 2b had no medical therapy after surgery (n = 
62). 
In Group 1, 19 patients died (annual mortality rate 3.6%) and 
in Group 2,17 patients died (mortality rate 2.4%, p = NS). Of the 
patients who died, approximately one half to two thirds in both 
Groups 1 and 2 died suddenly and the other one half to one third 
died because of congestive heart failure. The 10 year cumulative 
survival rate was 67% in Group 1, significantly smaller than that 
in Group 2 (84%, p < 0.05). In the subgroups, the 10 year 
Long-term follow-up of patients with hypertrophic cardio-
myopathy has been reported (1-7) to be dependent on the 
severity of outflow tract obstruction and the degree of 
impairment of left ventricular diastolic function. An im-
proved survival rate and symptomatic status has been ob-
served after surgical treatment of the outflow tract obstruc-
tion (1,3,8-14), but more recently, medical therapy has also 
yielded beneficial effects on the long-term course of patients 
with hypertrophic cardiomyopathy (I5). Before 1976 medical 
therapy of hypertrophic cardiomyopathy was based mainly 
on beta-adrenergic blocking agents, especially propranolol. 
Several studies (1-5,13,16,17) had documented a reduction 
of outflow tract obstruction and a positive effect on the 
clinical course and prognosis with this therapy. More re-
cently, an improved prognosis and clinical course were 
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survival rate was 67% in Group la, 80% in Ib (p < 0.05 versus 
la) and 65% in lc (p < 0.05 versus Ib). The 10 year survival rate 
was 100% in Group 2a (p < 0.05 versus la, Ib, lc) and 78% in 
Group 2b (p < 0.05 versus 2a). 
It is concluded that cumulative survival rate is significantly 
better in surgically than in medically treated patients. However, 
the survival rate among medically treated patients was better in 
those treated with verapamil than in those treated with propran-
olol or in untreated patients. The 10 year survival rate was similar 
in the medically treated patients receiving verapamil (80%) and 
the entire surgically treated group (84%, p = NS). The most 
favorable outcome was observed in surgically treated patients 
receiving long-term therapy with verapamil, probably as a result 
of the reduction of systolic pressure overload by septal myectomy 
and improvement in left ventricular diastolic function mediated by 
verapamil. 
(J Am Coli CardioI1991,'17:634-42) 
reported after long-term therapy with verapamil (5-7,13,17-
22). 
The purpose of this study was to evaluate, in a retrospec-
tive analysis, the effect of surgical and medical therapy on 
survival and symptomatic status of the 139 patients with 
hypertrophic cardiomyopathy followed up since 1%1 at the 
Medical Policlinic and the Clinic of Cardiovascular Surgery 
of the University Hospital in Zurich. 
Methods 
Study patients (Table 1). The study group consisted of 
139 patients with hypertrophic cardiomyopathy; 26 were 
female and 113 male. The mean age was 37 years (range 3 to 
66). The mean follow-up time was 8.9 years (range I to 28). 
Sixty patients who were managed medically (Group 1) and 
79 patients underwent operation (Group 2). Group I, which 
we termed the "medical group," was separated into three 
subgroups: Group la, 20 patients who received propranolol 
(average dose 160 mg/day range 40 to 280); Group Ib, 18 
patients who received verapamil (average dose 360 mg/day, 
range 120 to 480); and Group le, 22 patients who received no 
treatment because they had no symptoms or showed poor 
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Table 1. The 139 Study Patients 
n 
Total 139 
Group la 20 
Group Ib 18 
Group Ic 22 
Group 2a 17 
Group 2b 62 
Age (yr) 
37 :t 14 
42 :t 13 } 
40 :t 13 * 
32 :t 15 
41 :t 14 
36 :t 14 
Follow-Up (yr) 
8.9 ± 6.5 
7.8 :t 5.9 
9.1:t7.5 
7.8 :t 7.1 
9.3 ± 5.8 
9.5 :t 6.2 
*p < 0.05. Group I = medical therapy; Group 2 = surgical therapy (septal 
myectomy). Group la = propranolol treatment; Group Ib = verapamil 
treatment; Group Ic = no treatment; Group 2a = septal myectomy and 
verapamil; Group 2b = septal myectomy without verapamil. Age is given at 
the time of diagnosis. 
compliance. In the surgical group 17 patients (Group 2a) 
received verapamil (average dose 360 mg/day, range 120 to 480) 
because of persistent symptoms after septal myectomy and 62 
(Group 2b) received no medical therapy after operation (Table 
1). 
Patients with a systolic pressure gradient of more than 
50 mm Hg or clinical symptoms that could not be influenced 
by medical therapy underwent septal myectomy. Patients 
who had only mild outflow tract obstruction (pressure gra-
dient <50 mm Hg) with no or only mild symptoms were 
treated medically. Thus, in this regard the two groups are not 
really comparable, but because of the relatively small num-
ber of patients and the long time span of the study, random-
ization was not performed. 
All patients were informed about the potential risk and 
benefit from either therapy. Patients who underwent cardiac 
catheterization gave informed consent. 
Clinical examination. At entry into the study (time of 
diagnosis or preoperative evaluation), all patients were ex-
amined clinically. Functional status of the patients was 
described according to the New York Heart Association 
classification. The frequency of the most common symptoms 
in hypertrophic cardiomyopathy (angina pectoris, dyspnea 
on exertion, dizziness, syncope and palpitation) was deter-
mined. In all patients, heart rate and blood pressure were 
measured in the supine position. A rest electrocardiogram 
(ECG) was obtained routinely. The Sokolow-Lyon index 
was calculated as R in V 5 or V 6 + S in V \. One hundred 
twenty of the 139 patients underwent exercise testing. Phys-
ical working capacity was determined by bicycle ergometry 
as a percentage of the age-, gender- and height-adjusted 
normal value. A chest roentgenogram was obtained in all 
patients and the cardiothoracic ratio was calculated. Be-
cause Holter ECG monitoring was performed only in a few 
patients, these data are not reported. 
Cardiac catheterization. Of the 139 patients, 125 (all of 
Group 2 and 46 of Group 1) underwent cardiac catheteriza-
tion for diagnostic purposes and to assess the outflow tract 
gradient in the pre-echocardiography era, or to determine 
whether coronary artery disease was present. Cardiac cath-
eterization included right- and left-sided catheterization with 
determination of cardiac output by the Fick method, biplane 
left ventricular angiocardiography and coronary arteriogra-
phy. The systolic pressure gradient across the left ventricu-
lar outflow tract at rest and after provocation (postextrasys-
tolic potentiation, Val salva maneuver, isoproterenol 
infusion) was determined by simultaneous measurement of 
left ventricular (with the use of a transseptal catheter) and 
aortic pressures. Left ventricular volume was calculated 
according to the area-length method. 
Echocardiography. At entry, 70 patients underwent 
M-mode and two-dimensional echocardiography (Diasonics 
model CV-3400R). Diagnosis was based on the criteria of 
Maron et al. (23). Before 1978, when only M-mode echocar-
diography was available, all patients underwent catheteriza-
tion to establish the diagnosis. Nevertheless, 90% of all pa-
tients were evaluated invasively to exclude those with 
asymmetric hypertrophy from causes other than hypertrophic 
cardiomyopathy. Septal and posterior wall thickness, end-
systolic and end-diastolic internal chamber diameter of the left 
ventricle, systolic shortening of the internal chamber diameter 
and end-systolic diameter of the left atrium were measured 
(23). After 1983, the systolic pressure gradient across the left 
ventricular outflow tract was assessed quantitatively (24) by 
Doppler ultrasound (Hewlett-Packard model 77020 AC). Hy-
pertrophic cardiomyopathy was diagnosed exclusively by Dopp-
ler measurements in 14 of 60 patients in Group 1 and in no 
patient in Group 2. These patients were not evaluated inva-
sively because symptomatic status was mild and only minimal 
or no outflow tract obstruction was present as determined by 
Doppler echocardiography. 
Medical and surgical therapy. Patients were classified 
retrospectively into a medically and a surgically treated 
group. The policy for conservative (medical) or surgical 
treatment remained unchanged at our hospital over the years 
of the study and was: 1) Patients were treated medically 
when no or only a mild pressure gradient «50 mm Hg) with 
no or mild symptoms were present. Patients with a signifi-
cant pressure gradient (>25 but <50 mm Hg) or typical 
symptoms that responded well to medical therapy were 
followed up on medical treatment. 2) Patients were treated 
surgically if they had a resting pressure gradient of more than 
50 mm Hg or a pressure gradient after postextrasystolic 
potentiation of more than 100 mm Hg or when clinical 
symptoms were present that did not respond or insufficiently 
responded to medical therapy. Patients who did not respond 
to medical therapy either by a lessening of clinical symptoms 
or a reduction in systolic pressure gradient were referred for 
surgery (n = 37). Most medically treated patients received 
propranolol in the years before 1978 but received verapamil 
after 1978. In some patients medical therapy was switched 
from one to the other drug when no functional improvement 
was observed with the first one administered. Forty-two of 
the 79 patients who underwent myectomy were sent directly 
to surgery without significant medical therapy in the pres-
ence of severe outflow tract obstruction. 
Septal myectomy was performed by the transventricular 
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Table 2. Clinical Data of 139 Patients at Entry and at End of Follow-Up 
Sokolow-Lyon Index (mV) eTR pwe (% of normal) 
Entry End Entry End Entry End 
Group 1 3.3 ± 1.3 3.2 ± 1.3 0.51 ± 0.05 0.53 ± 0.07 81 ± 19 81 ± 20 
1a 3.2 ± 1.3 3.1 ± l.3 0.51 ± 0.05 0.54 ± 0.05 78 ± 19 77 ± 25 
1b 3.1 ± l.3 2.9 ± 1.2 0.51 ± 0.05 0.54 ± 0.09 74 ± 21 84 ± 23 
1c 3.5 ± 1.4 3.6 ± 1.3 0.50 ± 0.04 0.50 ± 0.06 91 ± 18 % ± 12 
Group 2 3.5 ± 1.2 0.52 ± 0.05 0.53 ± 0.06 80 ± 18 80 ± 17 
2a 3.8 ± l.l 0.51 ± 0.05 0.53 ± 0.06 84 ± 16 81 ± 18 
2b 3.2 ± 1.2 0.53 ± 0.04 0.53 ± 0.06 75 ± 19 78 ± 16 
'Left bundle branch block in 10 (60%) of 17 patients; tlef! bundle branch block in 21 (34%) of 62 patients; eTR = cardiothoracic ratio; pwe == physical 
working capacity; SM = septal myectomy. Groups are as defined in Table I. 
(n = 38; 1965 through 1979), the transaortic/transventricular 
approach (n = 7; 1973 through 1981) or the transaortic 
approach (n = 34) between 1966 through 1987. No patient 
died immediately after surgery, but one patient died 4 days 
after myectomy due to pericardial tamponade (perioperative 
mortality 1.3%). 
Follow-up. In 104 patients at least one further clinical 
examination was performed during the follow-up period. 
Thirty-five patients were followed up only by questionnaire 
because they refused reexamination or because they had 
changed their domicile. Follow-up information was obtained 
in all patients by the end of 1986 or later. The cause of death 
was determined by questioning relatives or the referring 
physician. Autopsy was performed only in a few patients and 
thus, these data are not included. 
Statistics. Data within each group and subgroup (entry 
and last follow-up data) were analyzed by the Student's t test 
for paired or unpaired variables. Differences among the 
subgroups were calculated by a one-way analysis of variance 
followed by the Scheffe test if the analysis was significant. 
Calculation of cumulative survival rates was performed as 
described by Anderson et al. (25). Relative frequencies were 
analyzed by the chi-square test. Annual mortality rate rep-
resents linearized rates per 100 patients per year. Values 
presented in the tables and figures are means ± SD. 
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Results 
Initial findings 
The patients were 3 to 66 years old. Eleven of the 79 
surgically treated and 3 of the medically treated patients 
were::; 15 years old. 
Clinical examination (Table 2, Fig. 1). At entry into the 
study, functional classification did not differ between Group 
2 (mean 2.1) and Group 1 (mean 1.8, P == NS) but Group 2 
differed significantly from Group 1 c (Group 2 versus 1 c, 2.1 
versus 1.6, p < 0.05). Clinical symptoms, such as angina 
pectoris, syncope, dyspnea on exertion, dizziness and pal-
pitation, were not observed more frequently at entry into the 
study in Group 1 than in Group 2. On entry into the study 
most of the patients in both groups were in sinus rythm (97% 
in Group 1 and 97% in Group 2); atrial fibrillation or flutter 
was observed in 3% in each group. The Sokolow-Lyon index 
was also similar in the two groups. Neither cardiothoracic 
ratio nor physical working capacity was significantly dif-
ferent between the two main groups and the five subgroups. 
Cardiac catheterization (Table 3). Group 1 and Group 2 
were not significantly different with regard to heart rate, left 
ventricular end-diastolic pressure, left ventricular ejection 
fraction and cardiac index. However, left ventricular peak 
systolic pressure and the pressure gradient across the left 
Figure 1. Functional classification accord-
ing to the New York Heart Association 
(NYHA) at entry and at the end offollow-up 
in 139 patients with hypertrophic cardiomy-
opathy. Group la = 20 patients treated with 
propranolol; I b = 18 patients treated with 
verapamil; Ic = 22 patients without any 
therapy; 2a = 17 patients with septal myec-
tomy and verapamil; 2b = 62 patients with 
septal myectomy without any medical ther-
apy. 
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Table 3. Hemodynamic Baseline Data in 93 Patients 
HR LVEDP LVSP dP EF Cl 
n (beats/min) (mm Hg) (mm Hg) (mm Hg) (%) (liters/min/m2) 
Group I 56 72 ± 12 16 ± 8 133 ± 28 17 ± 21 67 ± II 3.2 ± 0.7 
la 19 77 ± 17 15 ± 9 137 ± 24 22 ± 26 67 ± 12 3.4 ± 0.7 
Ib 18 70 ± 9 16 ± 8 129 ± 29 * II ± 8 68 ± 14 2.9 ± 0.5 
Jc 19 70 ± 10 18 ± 7 134 ± 30 18 ± 28 66 ± 7 3.4 ± 0.9 
Group 2 37 71 ± 9 22 ± 7 178 ± 39 70 ± 33 72 ± II 3.1 ± 0.8 
2a 17 72 ± 9 22 ± 6 182 ± 40 68 ± 34 76 ± 8 3.1 ± 0.8 
2b 20 70 ± 9 21 ± 7 172 ± 38 72 ± 31 68 ± 13 3.0 ± 0.7 
*p < 0.05 for Group I versus Group 2. CI = cardiac index: EF = ejection fraction: HR = heart rate: L VEDP = left ventricular end-diastolic pressure: 
L VSP = left ventricular peak systolic pressure: dP = pressure gradient at rest across the left ventricular outflow tract: SM = septal myectomy. Groups are defined 
in Table 1. 
ventricular outflow tract at rest were 133 and 17 mm Hg, 
respectively, in Group I and 178 and 70 mm Hg, respectively 
in Group 2 (p < 0.05). Nine of the 125 patients who 
underwent cardiac catheterization were found to have cor-
onary artery disease with significant stenosis (>50%) of one 
or more epicardial coronary vessels. 
Echocardiography (Table 4). The echocardiographic var-
iables (septal and posterior wall thickness, end-systolic and 
end-diastolic internal chamber diameter of the left ventricle, 
systolic shortening of internal chamber diameter and end-
systolic left atrial diameter) did not show a significant 
difference between the two main groups and the five sub-
groups. 
Follow-Up Data 
Survival rates (Tables 5 and 6). During follow-up. 36 
patients died: 19 in Group I (annual mortality rate 3.6%) and 
17 in Group 2 (annual mortality rate 2.4%, p = NS). Most 
patients died suddenly (13 in Group I and six in Group 2, 
p = NS) or as a result of congestive heart failure (three in 
Group I and five in Group 2. p = NS) (Table 5). Among the 
II pediatric patients (3 to 15 years old) who underwent 
operation, four (36%) died during follow-up. 
The 5, 8 and 10 year cumulative survival rates were 
Table 4. Echocardiographic Data in 139 Patients 
Dcd(cm) Th,(cm) 
Entry End Entry End 
significantly higher (p < 0.05) in Group 2 than in Group 1. 
The lO-year survival rate was 84% in Group 2 and 68% in 
Group I (Fig. 2). In Group I, survival rates after 5 and 8 
years were significantly better in the verapamil-treated group 
than in the other two subgroups (p < 0.05): 88% and 88% at 
5 and 8 years, respectively, in Group Ib (verapami\), 81% 
and 74% in Group la (propranolol) and 72% and 65% in 
Group Ic (nontreated). Patients treated with propranolol 
showed a better survival rate during the first 2 years of the 
study than did those without treatment ( p < 0.05) (Fig. 3). 
There was no statistical difference between the 5 and 10 year 
survival rates of Group 2 (96% and 84%) and those of Group 
Ib (verapamil) (88% and 80%. respectively) (Table 6). The 17 
Group 2 patients receiving verapamil (Group 2a) had the best 
survival rates: 100% after 5 and 8 years (maximai follow-up 
16 years), compared with 92% and 85% in the 62 patients in 
Group 2b (both p < 0.05) (Fig. 4). 
Clinical examination (Table 2). In Group I, functional 
classification did not change significantly during the fol-
low-up period, either in the entire medical group or in the 
subgroups. Group 2 showed an improvement in functional 
classification from preoperatively to postoperatively (2.1 
versus 1.6 at the end of the observation period) (p < 0.05) 
(Fig. I). Patients in Group 2 had angina pectoris, dizziness 
Thp(cm) LA (cm) Sh(%) 
Entry End Entry End Entry End 
Group I 4.5 ± 0.8 4.5 ± 0.8 1.8 ± 0.4 2.0 ± 0.4 1.1 ± 0.2 1.2 ± 0.2 3.9 ± 0.8 4.6 ± 1.0 42 ± 7 43 ± 8 
n = 48 n = 43 n = 50 n = 46 n = 50 n = 44 n = 49 n = 46 n = 45 n = 44 
la 4.4 4.4 2.0 1.9 1.2 J.2 4.1 4.8 46 42 
Ib 4.5 4.5 1.9 2.1 1.0 1.2 3.9 4.8t 43 42 
Ic 4.8 4.5 1.7 2.0 1.1 1.2 3.8 4.lt 44 44 
Group 2 4.5 ± 0.8 5.1 ± 0.8 1.9 ± 0.6 1.7 ± OJ 1.2 ± 0.2 1.1±0.1 4.3 ± 1.0 4.7 ± 0.9 41 ± 7 39 ± 9 
n = 20 n = 39 n = 24 n = 39 n = 22 n = 40 n = 21 n = 39 n = 21 n = 37 
2a 4.6 5.2 1.9 1.7 1.1 1.2 4.1 4.8 41 40 
2b 4.5 5.2 2.0 1.7* 1.2 1.2 4.5 4.6 42 39 
*p < 0.05 versus entry: tp < 0.01 versus entry. Oed = end-diastolic internal chamber diameter of the left ventricle: LA = left atrial diameter: Sh(%) = systolic 
percent shortening of the internal chamber diameter measured at the tip of the mitral valve: SM = septal myectomy: Thp = posterior wall thickness: Th, = septal 
wall thickness. Groups are defined in Table I. 
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Table 5. Causes of Death 
Sudden Death Heart Failure Other 
Group I 22% (13/60) 5% (3/60) 5% (3/60) 
la 20% (4/20) 5% (1120) 10% (2/20) 
Ib 17% (3/18) 0% (0/18) 6% (1/18) 
Ie 27% (6/22) 9% (2/22) 0% (0/22) 
Group 2 8% (6179) 6% (5179) 8% (6179) 
2a 6% (1/17) 0% (0/17) 0% (0117) 
2b 8% (5/62) 8% (5/62) 10% (6/62) 
There were no significant differences regarding cause of death. Groups are 
defined in Table I. 
and syncope less frequently postoperatively than preopera-
tively (55% versus 44%, 28% versus 19% and 10% versus 
0%, respectively, all p < 0.05). None of the two main groups 
or five subgroups had a significant change in physical work-
ing capacity or cardiothoracic ratio. The Sokolow-Lyon 
ECG index of ventricular hypertrophy did not change signif-
icantly during the follow-up, nor did it differ among the 
Group I subgroups at the end of the study. Because 39% of 
all surgically treated patients had left bundle branch block, 
the Sokolow-Lyon index was not determined postopera-
tively in Group 2. 
Echocardiography (Table 4). During follow-up, left atrial 
diameter increased from 4.1 to 4.8 cm in subgroup I a 
(propranolol) (p < 0.01) and from 3.9 to 4.8 cm in subgroup 
Ib (verapamil) (p < 0.01). After surgery, septal wall thick-
ness decreased from 2.0 to 1.7 cm in Group 2b (surgical 
therapy, no verapamil, p < 0.05). Between Groups 1 and 2 
only one echocardiographic variable showed a significant 
difference at the end of the study: left ventricular end-
diastolic diameter was larger in Group 2 than in Group la 
(5.1 versus 4.4 cm, p < 0.05). However, left ventricular 
end-diastolic internal chamber diameter was not different 
between the Groups I and 2 as a whole. 
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Table 6. Survival Rates: Group Ib Versus Group 2 
Follow-up 5 Year 10 Year 
n (yr) Survival Survival 
Verapamil medical 18 9.1 88% 80% 
group (lb) 
Surgical 79 9.4 96% 84% 
group (2) 
There were no significant differences between the two groups at either 5 or 
10 years of follow-up. 
Discussion 
The I-year mortality rate in patients with hypertrophic 
cardiomyopathy is 3 to 8% (2,4,17,26-28), and the 5-year 
survival rate is 55 to 78% (4,17,29). The most common cause 
of death is sudden cardiac death due to arrhythmias, fol-
lowed by congestive heart failure. Patients at high risk for 
sudden death are young, have a positive family history and 
have no or only mild outflow tract obstruction (5). To control 
symptoms and possibly to improve prognosis, several ther-
apeutic approaches (15), including surgical resection of the 
hypertrophied septum (8,9) or mitral valve replacement 
(30,31), have been proposed. Medical therapy was based for 
many years on beta-adrenergic blocking drugs (2,4,32), but 
recently calcium antagonists have become popular (18-22). 
Medical Therapy 
Propranolol. Propranolol was introduced in the early 
1960s (32). Its main pharmacologic effect is related to a 
reduction in heart rate and contractility with a concomitant 
decrease in outflow tract obstruction. Propranolol did not 
affect the survival rate in most studies (5,16,17), although 
Frank et al. (4) reported an improved survival rate in patients 
receiving very large doses (460 mg/day) (Table 7). Five-year 
15 
Figure 2. Cumulative survival rates of the 139 patients 
with hypertrophic cardiomyopathy. Group 1 = medi-
cal therapy (n = 60); Group 2 = surgical therapy (n = 
79). The average follow-up was 8.9 years for the entire 
study group, 8.2 years for Group 1 and 9.4 years for 
Group 2. Group 2 had higher 2, 5, 8 and 10 year 
survival rates than did Group 1. 
SEILER ET AL. 639 lACC Vol. 17, No.3 
March 1, 1991:634-42 LONG-TERM FOLLOW-UP IN HYPERTROPHIC CARDIOMYOPATHY 
Figure 3. Cumulative survival rates of Group I. Group 
la was treated with propranolol, Ib with verapamil, Ic 
received no therapy. The average follow-up time was 
8.2 years for the entire medical group, 7.8 years for 
Group la, 9.1 years for Group Ib and 7.8 years for 
Group Ie. Group lb had better survival rates than la 
or Ie (p < 0.05). 
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survival rates varied between 76% (16) and 90% (4), whereas 
in untreated patients 5-year survival varied between 55% and 
78% (4,17,29). In the present study, the 2-year survival rate 
was better with propranolol than without medical treatment. 
A long-term beneficial effect of propranolol on survival 
could, however, not be substantiated because 5- and to-year 
survival rates for patients treated with propranolol were 81 % 
and 67%, respectively, whereas in the untreated group they 
were 72% and 65%, respectively (Table 7). 
Verapamil. Kaltenbach et al. (33) first reported on the 
therapeutic effect of verapamil on symptoms and left ven-
tricular hypertrophy in patients with hypertrophic cardiomy-
opathy and their findings have been confirmed by others 
(17,18,22). Most investigators have reported a high survival 
rate after chronic therapy with verapamil; Rosing et al. (21), 
however, reported an annual mortality rate of 6%. Their 
follow-up period was the shortest (1.2 years) of all studies 
summarized in Table 7. In the other studies (17,18,22), 
annual mortality rates varied between 1.8% and 2.2%. In the 
present analysis it was 2.3%. The to-year survival rate was 
90% in the study of Hopf and Kaltenbach (22) and 80% in the 
present study. Among the medically treated patients who 
received propranolol or verapamil and the untreated patients 
(Fig. 3), the best follow-up results were in the verapamil-
treated patients, with a significantly (p < 0.05) higher sur-
vival rate after 8 years (88%) than in the propranolol-treated 
(74%) or untreated subgroups (65%). The mode of action of 
verapamil is not clear but appears to be related either to 
improved relaxation with an increased early filling rate (34), 
improved subendocardial perfusion (7), an antiarrhythmic 
effect (19), or a reduction in left ventricular asynchronous 
wall motion (34,35). 
Surgical Therapy 
Surgical management of hypertrophic obstructive cardio-
myopathy was introduced in the late 50s by Cleland (8); he 
5 10 15 
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performed myotomy/myectomy of the hypertrophied septum 
using a trans ventricular approach. This technique was later 
adapted by others (10,11,36), and transaortic myectomy has 
become the treatment of choice for severely symptomatic 
patients with a large outflow tract pressure gradient. Mitral 
valve replacement as an alternative therapy for hypertrophic 
cardiomyopathy has been recommended (30,31), but has not 
been used by most surgeons except in patients with severe 
mitral regurgitation or clear valvular alterations (11,36). The 
1-year mortality rate was low after septal myectomy, ranging 
between 2.6% and 4.4% (9,1l,36,37); it was 2.7% in the 
present analysis (Table 7). Most authors have reported 
mortality rates between 2% and 3%, although McIntosh and 
Maron (II) reported a mortality rate of 4.4%/year. The 
perioperative mortality rate varies between 1.3% (present 
study) and 17.6% in the elderly (38); the average of five 
reports is 5%. Five- and to-year survival rates including 
perioperative mortality were 96% and 84%, respectively, in 
the present study (Table 7). Similar data were reported by 
Kuhn et al. (29); however, they excluded perioperative 
mortality. In our study, there was a tendency toward fewer 
sudden cardiac deaths after surgery (Table 5) than with 
medical therapy (p = NS). The mechanism of this favorable 
result is not clear but may be related to regression of 
secondary hypertrophy with less subendocardial ischemia 
after removal of the pressure burden (39). 
Medical Versus Surgical Therapy 
Cumulative survival rates were consistently better after 
myectomy than after medical therapy, including untreated 
and treated (propranolol and verapamil) patients (Fig. 2). 
After 5 years the cumulative survival rate was 96% in the 
surgical and 78% in the medical group; the respective data 
after to years were 84% and 68%. The two survival curves 
approached each other after 13 years of follow-up. In abso-
lute terms, 19 (32%) of 60 patients in the medically treated 
640 SEILER ET AL. lACC Vol. 17. No.3 
LONG-TERM FOLLOW-UP IN HYPERTROPHIC CARDIOMYOPATHY March I. 1991:634-42 
Table 7. Literature Review of the Course of Hypertrophic Cardiomyopathy in Patients With or Without Therapy 
Follow-up 
n (years) Deaths 
No therapy 
Frank 1968 (28) 98 2.9 10 
Loogen 1978 (27) 47 6.7 II 
Shah 1974 (2) 31 5.2 5 
Frank 1978 (4) 10 5.0 4 
Haberer 1983 (17) 20 6.4 8 
Kuhn 1983 (29) 27 6.4 7 
Present data 1990 22 7.8 8 
Propranolol 
Shah 1974 (2) 101 4.7 19 
Frank 1978 (4) 22 5.0 0 
Kuhn 1978 (16) 168 5.2 28 
Canedo 1981 (3) 33 5.7 
McKenna 1981 (5) 170 6.0 39 
Haberer 1983 (17) 15 7.0 4 
Kuhn 1983 (29) 140 4.6 7 
Present data 1990 20 7.8 7 
Verapamil 
Hopf 1982 (18) 41 2.7 2 
Rosing 1982 (21) 42 1.2 
Haberer 1983 (17) 15 3.7 I 
Hopf 1987 (22) 84 4.3 8 
Present data 1990 18 9.1 4 
Septal myectomy/myotomy 
Senning 1976 (9) 39 2.9 
Maron 1983 (37) 240 35 2 
Mcintosh 1988 (11) 123 11.5 63 
Schulte 1988 (36) 283 6.2 39 
Present data 1990 62 95 17 
Myectomy + verapamil 
Present data 1990 17 9 
TA = transaortic approach; TV = trans ventricular. 
group and 17 (22%) of79 in the surgically treated group died 
during the follow-up of approximately 9 years. Although the 
absolute values are similar, only one-fifth of all patients in 
the surgically treated but one-third in the medically treated 
group died. Thus, not only are cumulative survival rates 
better in the surgical than in the medical group but the 
percent of patients who died during the follow-up period was 
also lower. 
Role of verapamil. The survival rates of the surgically 
treated patients are only slightly and insignificantly better 
than those of the medically treated patients who received 
verapamil after 5 (96% versus 88%) and 10 years (84% versus 
80%) (Table 6). Some investigators (18,22) have concluded 
that verapamil therapy is as effective as surgery and that 
surgical intervention is no longer necessary even in severely 
symptomatic patients with a high pressure gradient. On the 
basis of this observation (Table 6), the effect of verapamil 
treatment on cumulative survival rates in surgically treated 
patients was evaluated (Fig. 4). Surprisingly, cumulative 
survival rates after 5 and 8 years were 100%; the only patient 
5-/IO-year 
Mortality survival 
(%/year) (%) Therapy 
3.5 -/-
3.5 -/-
3.1 -/-
8.0 74/-
6.3 55/-
4.0 78/-
4.7 72/65 
4.0 -/- Beta-blocking agents 
0 90/75 Propranolol (460 mg/day) 
3.2 76/- Beta-blocking agents 
0.5 -/- Propranolol (460 mg/day) 
3.8 -/- Beta-blocking agents 
3.8 80/- Propranolol (175 mg/day) 
2.6 -/- Propranolol (? mg/day) 
4.5 81167 Propranolol (160 mg/day) 
1.8 -/- Verapamil (500 mg/day) 
6.0 -/- Verapamil (240-640 mg/day) 
1.8 93/- Verapamil (360 mg/day) 
2.2 -/90 Gallopamil (158 mg/day) 
2.3 88/80 Verapamil (360 mg/day) 
2.6 -/- Septal myectomy (TV) 
2.7 -/- Septal myectomy (T A) 
4.4 -/- Septal myectomy (T A) 
2.2 80/- Septal myectomy (T A) 
2.7 96/84 Septal myectomy (TV/TA) 
0.6 100/00 Septal myectomy + verapamil 
(120-360 mg/day) 
who died among the 17 treated surgically and then with 
verapamil (Group 2a) died after 16 years of follow-up. This 
excellent result must be interpreted with caution because the 
number of observations is relatively small. The indication for 
therapy was based on clinical symptoms rather than hemo-
dynamic findings; nevertheless, the favorable outcome may 
be explained by the combined action on systole (myectomy) 
and diastole (verapamil). Whereas surgery is known to 
reduce the systolic pressure gradient and diastolic filling 
pressure (12,39), verapamil has been shown to improve left 
ventricular function (34,35). Whether improvement of im-
paired diastolic function was the basis of the excellent 
survival in Group 2a or whether primarily a reduction of 
arrhythmias with consecutive reduction of sudden death was 
the predominant mechanism remains open to discussion. 
Effect of therapy on clinical and laboratory findings. An 
improvement in functional classification could be observed 
only after myectomy but not with medical therapy (Fig. 1). 
This effect is probably related to the reduction in systolic 
pressure gradient and diastolic filling pressure that is asso-
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Figure 4. Cumulative survival rates of the 60 patients ~ 
treated medically (Group I) and the 79 treated surgi- a: 
cally (Group 2). The subgroup of Group 2 patients who ...J « 
were subsequently treated with verapamil (120 to 360 > 70 
mg/day) had the best survival rate: they were followed :> a: 
by the surgical group that did not receive verapamil ::l 
and then by Group I. The average follow-up duration 
(f) 60 
w 
was 8.2 years for Group I. 9.3 years for Group 2. 9.4 > 
years for Group 2 patients treated with verapamil and f= « 50 
9.5 years for Group 2 patients not treated with vera- ...J ::l 
pamil (p < 0.05). ~ 
::l 40 () 
30 
0 
ciated with myectomy but is not seen after medical therapy 
(21). Cardiothoracic ratio. physical working capacity and 
Sokolow-Lyon ECG index (Table 2) remained unchanged in 
all groups throughout the follow-up period. There is a 
reported consensus (9.12.13,37) that myectomy/myotomy 
lessens cardiac symptoms and improves functional classifi-
cation even over long-term follow-up. 
The effect of beta-adrenergic blockers on functional sta-
tus in hypertrophic cardiomyopathy is controversial. Earlier 
studies by Frank et al. (3.4) showed a significant lessening of 
symptoms with large doses of propranolol. whereas more 
recent studies (5.17.20) did not find improvement in func-
tional classification during long-term therapy. Several inves-
tigators (18,19,29.40) have reported a decrease in clinical 
symptoms with long-term verapamil treatment. However. 
the present study with a mean follow-up period of 9.7 years 
did not show any lessening of clinical symptoms. although in 
most patients temporary clinical improvement with initial 
verapamil therapy was seen. 
A decrease in septal H'al/ thickness was observed with 
M-mode echocardiography in patients receiving long-term 
verapamil therapy (19.22), whereas posterior wall thickness 
remained unchanged (19) or decreased (22). Myectomy was 
shown (41) to be associated with a significant decrease in 
septal wall thickness, but at the same time left ventricular 
end-diastolic internal chamber diameter increased signifi-
cantly. This finding could be due to the reduction in muscle 
mass or the occurrence of asynchrony caused by left bundle 
branch block or both. However. no change in septal or 
posterior wall thickness was observed during medical ther-
apy in the present study. 
Limitations of the study. One major limitation of the 
present study is that it is a retrospective analysis comparing 
two groups that are not necessarily comparable. In this 
regard, systolic pressure gradient and peak systolic pressure 
n=16 n=14 n=12 n=9 n=7 ",1 
1] 
n=18 
--0 -surgical group (n=79) 
--0 - medical group (n=60) 
~surgical group + verapamil (n=17) 
-:;:"surgical group without verapamil (n=62) 
.. P<O.05 
5 10 15 
TIME (years) 
were significantly different between the medically and sur-
gically treated patients (Table 3). This is due to patient 
selection: patients with a large pressure gradient underwent 
operation and those with a small gradient did not. Because of 
the relatively small number of patients and the long obser-
vation period of up to 28 years, randomization could not be 
performed in a reasonable time span. and thus. all follow-up 
studies in patients with hypertrophic cardiomyopathy are 
based on retrospective data. 
Conclusions. In severely symptomatic patients and those 
with hypertrophic cardiomyopathy and large pressure gradi-
ents, clinical follow-up results are best with combined treat-
ment with septal myectomy and chronic verapamil therapy. 
However. mildly symptomatic patients with no or mild 
outflow tract obstruction probably benefit most from treat-
ment with verapamil. 
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